Tardive dyskinesia in a patient treated with quetiapine.

Abstract

Quetiapine is an atypical antipsychotic that is believed to have a low D2 binding affinity in striatal and extrastriatal regions. We report the case of a female patient with the diagnosis of schizoaffective disorder (using DSM-IV-TR criteria) who initially received amisulpride for 3 months, discontinued gradually because of persistent and distressing extra-pyramidal symptoms, and who developed tardive dyskinesia 3 months later after the initiation of quetiapine. A trial with ziprasidone resulted in a further worsening of tardive dyskinesia symptoms. A further trial with aripiprazole, improved her tardive dyskinesia symptoms. Although, it is under consideration the possibility that the improvement could have been due to the discontinuation of quetiapine, we conclude that aripiprazole improved the TD symptoms.

• Authors: Emmanouil Rizos, Athanassios Douzenis, Rossetos Gournellis, Christos Christodoulou, Lefteris P Lykouras
• Journal: The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (World J Biol Psychiatry) Vol. 10 Issue 1 Pg. 54-7 ( 2009) ISSN: 1562-2975 [Print] England
• PMID: 19673087 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antipsychotic Agents
• Dibenzothiazepines
• Piperazines
• Quinolones
• Thiazoles
• Quetiapine Fumarate
• ziprasidone
• Sulpiride
• Amisulpride
• Aripiprazole

Topics

• Amisulpride
• Antipsychotic Agents (adverse effects, therapeutic use)
• Aripiprazole
• Basal Ganglia Diseases (chemically induced)
• Dibenzothiazepines (adverse effects, therapeutic use)
• Dyskinesia, Drug-Induced (drug therapy, etiology)
• Female
• Humans
• Middle Aged
• Piperazines (adverse effects, therapeutic use)
• Psychotic Disorders (drug therapy, psychology)
• Quetiapine Fumarate
• Quinolones (therapeutic use)
• Sulpiride (adverse effects, analogs & derivatives, therapeutic use)
• Thiazoles (adverse effects, therapeutic use)